B Cells That Produce Immunoglobulin E Mediate Colitis in BALB/c Mice

被引:42
作者
Hoving, Jennifer C. [1 ,2 ]
Kirstein, Frank [1 ,2 ]
Nieuwenhuizen, Natalie E. [1 ,2 ]
Fick, Lizette C. E. [1 ,2 ]
Hobeika, Elias [3 ,4 ,5 ]
Reth, Michael [3 ,4 ,5 ]
Brombacher, Frank [1 ,2 ]
机构
[1] Univ Cape Town, Int Ctr Genet Engn & Biotechnol, ZA-7925 Cape Town, South Africa
[2] Univ Cape Town, Div Immunol, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa
[3] Univ Freiburg, Fac Biol, Ctr Biol Signaling Studies, D-79106 Freiburg, Germany
[4] Univ Freiburg, Fac Biol, Dept Mol Immunol, D-79106 Freiburg, Germany
[5] Max Planck Inst Immunobiol, Freiburg, Germany
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
Immune Regulation; IBD; Inflammatory Bowel Disease; T-Cell Signaling; INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; T-CELLS; OXAZOLONE COLITIS; IL-4; RECEPTOR; IGE; INTERLEUKIN-13; ACTIVATION; MODEL; ANTIBODIES;
D O I
10.1053/j.gastro.2011.09.044
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Induction of colitis in mice by administration of oxazolone is mediated by T-helper (Th) 2 cells and has features of human ulcerative colitis. We investigated whether activation of interleukin (IL)-4R alpha on T and B cells determines their effector functions and mediates oxazolone-induced colitis. METHODS: We studied induction of colitis with oxazolone in wild-type mice and those with CD4(+) T cells that did not express IL-4R alpha (Lck(cre)IL-4R alpha(-)/(lox)). We also generated mice with B cells that did not express IL-4R alpha (mb1(cre)IL-4R alpha(-)/(ox)) and studied induction of colitis. RESULTS: Lck(cre)IL-4R alpha(-)/(lox) mice did not develop colitis in response to oxazolone, and their levels of IL-4, IL-13, and immunoglobulin (Ig) E were reduced. Adoptive transfer of naive, wild-type CD4(+) Th cells depleted of natural killer T cells to Lck(cre)IL-4R alpha(-)/(lox) mice restored their susceptibility to colitis. In contrast, Lck(cre)IL-4R alpha(-)/(lox) mice maintained their protection against colitis when IL-13-deficient CD4(+) T cells were transferred. These findings indicate that development of colitis involves not only natural killer T-cell functions, but also requires IL-13 production by CD4(+) T helper cells. Mb1(cre)IL-4R alpha(-)/(lox) mice, which cannot produce IgE, were also protected against oxazolone-induced colitis. Blocking IgE binding significantly reduced mast cell numbers in colons and protected wild-type BALB/c mice from the onset of colitis. CONCLUSIONS: IL-4 appears to induce CD4(+) Th2 cells to produce IL-13 and B cells to produce IgE, which together mediate oxazolone-induced colitis in mice.
引用
收藏
页码:96 / 108
页数:13
相关论文
共 55 条
  • [1] Allergy and hypersensitivity mechanisms of allergic disease - Editorial overview
    Akdis, Cezmi A.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (06) : 718 - 726
  • [2] [Anonymous], HDB LAB ANIMAL MANAG
  • [3] ANTI-IGE MONOCLONAL-ANTIBODIES DIRECTED AT THE FC-EPSILON RECEPTOR-BINDING SITE
    BANIYASH, M
    KEHRY, M
    ESHHAR, Z
    [J]. MOLECULAR IMMUNOLOGY, 1988, 25 (08) : 705 - 711
  • [4] Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease
    Bischoff, SC
    Wedemeyer, J
    Herrmann, A
    Meier, PN
    Trautwein, C
    Cetin, Y
    Maschek, H
    Stolte, M
    Gebel, M
    Manns, MP
    [J]. HISTOPATHOLOGY, 1996, 28 (01) : 1 - 13
  • [5] Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4
    Boirivant, M
    Fuss, IJ
    Chu, A
    Strober, W
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (10) : 1929 - 1939
  • [6] The immunological and genetic basis of inflammatory bowel disease
    Bouma, G
    Strober, W
    [J]. NATURE REVIEWS IMMUNOLOGY, 2003, 3 (07) : 521 - 533
  • [7] Brombacher F, 2000, BIOESSAYS, V22, P646, DOI 10.1002/1521-1878(200007)22:7<646::AID-BIES7>3.0.CO
  • [8] 2-9
  • [9] Bronchial hyperreactivity and allergic status in inflammatory bowel disease
    Ceyhan, BB
    Karakut, S
    Cevik, H
    Sungur, M
    [J]. RESPIRATION, 2003, 70 (01) : 60 - 66
  • [10] COFFMAN RL, 1986, J IMMUNOL, V136, P4538